FDA 2017 First Generics Approvals Retain India Imprint
Executive Summary
Indian companies continued to have marked presence in list of first generics approved by US FDA in 2017; clearances include some limited competition drugs and complex products that are vital for Indian firms as they transition their portfolios away from 'plain vanilla' generics.
You may also be interested in...
Copaxone 40mg Generic: FDA Exceeds Mylan's Expectations
FDA approves the product well before Mylan's prediction of 2018.
Complex ANDAs: Early Meetings With FDA Can Generate Bonus Communication
By conducting a product development or pre-submission meeting, sponsors can receive a mid-review cycle meeting for a complex product ANDA.
Afrigen MD: WTO IP Waiver Important From ‘Freedom To Operate’ Standpoint
Afrigen’s MD, Petro Terblanche, discusses the operational freedom that the WTO intellectual property waiver provides for its COVID-19 vaccine being developed under the wider WHO-backed mRNA technology transfer hub initiative. The executive doesn’t anticipate big pharma pushback but says the alliance will “test the system”, though others believe the waiver in its current form doesn’t count for much.